Rafael Holdings Inc - Ordinary Shares - Class B Aktie News

Trappsol® Cyclo™ erreichte keine statistische Signifikanz, zeigte jedoch einen in Richtung positiv verlaufenden Behandlungseffekt gegenüber Placebo beim primären Endpunkt der Veränderung der 4‑Domänen NPC Clinical Severity Scale (4DNPCSS) nach Woche 96. Eine vordefinierte Analyse bei Patienten, die eine Hintergrundtherapie mit miglustat und/oder Leucin erhielten, was etwa 83 % der Studienpopula...

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026.

Topline results are expected to be announced in second half of calendar 2026 The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026 The company has received acknowledgement from the FDA that our US Expanded Access Program (EAP) can proceed NEWARK, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced th...

License of the MIT patent strengthens Rafael's intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer's Disease License of the MIT patent strengthens Rafael's intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer's Disease